NP
Potter N E
King's College London, Institute of Cancer Research, University College London
Research areas: Medicine · Hematology · Acute Myeloid Leukemia Research · Retinoids in leukemia and cellular processes · Acute Lymphoblastic Leukemia research
0000-0002-8256-9350
Employment
-
King's College London Research Fellow2021 - Present
-
King's College London Healthcare Scientist/ Post Doctoral Training Fellow2016 - 2021
-
Institute of Cancer Research Post Doctoral Training Fellow2012 - 2016
-
Institute of Cancer Research Post Doctoral Training Fellow2009 - 2012
-
University College London Post Doctoral position2006 - 2009
Education
Education history is unavailable.
Projects & Funding
-
Optimise-FLT3 Study: Optimising therapy for patients with FLT3-mutated Acute Myeloid Leukaemia Cancer Research UK2024 - 2031
-
Sub-clonal architecture at a single cell level in acute myeloid leukaemia Gabrielle’s Angel Foundation for Cancer Research2013 - 2014
Publications (39)
- Blinatumomab for measurable residual disease relapse in acute myeloid leukemia with t(8;21) translocation: the BlinAML Trial. Save
- ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia. Save
- Safety and efficacy of combining midostaurin and gemtuzumab ozogamicin with induction chemotherapy in FLT3-mutated AML Save
- Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML Save
- A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1 mut AML in MRDneg remission after intensive induction. Save
- Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials. Save
- Pretransplant MRD detection of fusion transcripts is strongly prognostic in KMT2A-rearranged acute myeloid leukemia Save
- Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML Save
- Recommendations from the AML molecular MRD expert advisory board Save
- Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission Save
- Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations. Save
- Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML. Save
- Pitfalls in Diagnosis: JMML versus KMT2A Rearranged Juvenile AML Save
- Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based non-intensive therapy Save
- FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML Save
- Assessment of acute myeloid leukemia molecular measurable residual disease testing in an interlaboratory study Save
- A Randomised Comparison of CPX-351 and FLAG-Ida in Adverse Karyotype AML and High-Risk MDS: The UK NCRI AML19 Trial. Save
- Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome Save
- Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR) Save
- Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia Save